This Article Full Text (PDF) References Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Add to Saved Citations Download to citation manager Request Permissions Request Reprints Add to My Marked Citations Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Citing Articles via Scopus Google Scholar Articles by Ernst, E. Articles by Resch, K.L. Search for Related Content PubMed PubMed Citation Articles by Ernst, E. Articles by Resch, K.L. Social Bookmarking                         What's this?

Does Pentoxifylline Prolong the Walking Distance in Exercised Claudicants? A Placebo-Controlled Double-Blind Trial

Department of Physical Medicine and Rehabilitation, University of Vienna, Vienna, Austria

L. Kollár, M.D.

Department of Vascular Surgery, Medical School, Pécs, Hungary

K.L. Resch, M.D.

Hemorheology Research Laboratory, Department of Physical Medicine, LM University of Munich, Munich, Germany

The aim of this study was to test whether in claudicants oral pentoxifylline, given for twelve weeks in addition to physical exercise, prolongs the walking distance more than placebo plus exercise. Forty outpatients were randomized into group A (2 x 600 mg oral pentoxifylline per day) or group B (placebo). Both groups received the same exercise program in addition. The maximal and painfree walking distances and blood viscosity were measured. Intergroup dif ferences in terms of blood viscosity reached the level of significance only after twelve weeks (p=0.006 at shear rate of 94.5 s-1), but values of group A continu ously decreased and those of group B continuously increased. After one and eight weeks, but not after twelve weeks, the maximal walking distances were significantly longer in group A than in group B. At no point were there signifi cant intergroup differences in terms of painfree walking distance. The data suggest that pentoxifylline is clinically effective in claudicants even when given in addition to exercise. The benefit of drug plus physical therapy compared with exercise alone could be observed mainly in the first weeks of treatment and may wear off during long-term therapy.

Angiology, Vol. 43, No. 2, 121-125 (1992)
DOI: 10.1177/000331979204300205


CiteULike    Complore    Connotea    Del.icio.us    Digg    Reddit    Technorati    Twitter    What's this?

This article has been cited by other articles:

				K. Casey, B. H. Tonnessen, W. C. Sternbergh III, and S. R. Money Medical Management of Intermittent Claudication Vascular and Endovascular Surgery, September 1, 2004; 38(5): 391 - 399. [Abstract] [PDF]

				D. L. Dawson, Qintian Zheng, S. A. Worthy, B. Charles, and D. V. Bradley Failure of Pentoxifylline or Cilostazol to Improve Blood and Plasma Viscosity, Fibrinogen, and Erythrocyte Deformability in Claudication Angiology, September 1, 2002; 53(5): 509 - 520. [Abstract] [PDF]

				E. Ernst Pentoxifylline for Intermittent Claudication: A Critical Review Angiology, May 1, 1994; 45(5): 339 - 345. [Abstract] [PDF]

				D. J. Effeney, J. A. Stokes, and H. M. Trenerry The Trials and Tribulations of Pentoxifylline Perspectives in Vascular Surgery and Endovascular Therapy, January 1, 1992; 5(2): 123 - 137. [PDF]